Kulpeng, Wantanee <br/><br/>
Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand.  [electronic resource] 

 -  Clinical therapeutics  Apr 2014 
 - 534-43 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1879-114X 
<br/><br/><label>Standard No.: </label>10.1016/j.clinthera.2014.02.008  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Budgets<br/>Cost-Benefit Analysis<br/>Dasatinib--economics<br/>Drug Costs<br/>Humans<br/>Imatinib Mesylate--economics<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Leukemia, Myeloid, Chronic-Phase--drug therapy<br/>Markov Chains<br/>Protein Kinase Inhibitors--economics<br/>Pyrimidines--economics<br/>Quality of Life<br/>Quality-Adjusted Life Years<br/>Thailand